M. Charokopou - Concepedia

Author

M. Charokopou

UCB Pharma (Belgium)

Also Known As

M Charokopou, M. Charokopou, Mata Charokopou

Publications

574

Citations

H-Index

Concepts

All Affiliations

UCB Pharma (Belgium)Pharmerit (Netherlands)AstraZeneca (United Kingdom)AstraZeneca (Sweden)Bristol-Myers Squibb (France)

About

M. Charokopou is an author at UCB Pharma (Belgium) specializing in health policy, public health, and orthopaedics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	1	1	34
2	Medicine	1	1	17
3	Public Health	1	1	34
4	Health Policy	1	1	34
5	Orthopaedics	1	1	17

M. Charokopou

Publications

270

Citations

H-Index

Page 1

	Year	Citations
Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older Emma Söreskog, O. Ström, Anna Spångéus, Bone	2020	71
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective M. Charokopou, Phil McEwan, Steven Lister, BMC Health Services Research	2015	40
The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus M. Charokopou, Phil McEwan, Steven Lister, Diabetic Medicine	2015	35
Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006–2013 M. Charokopou, István Májer, Johan de Raad, Value in Health Substance AbuseHarm ReductionHealth PolicyHealth EconomicsHealth Care Reimbursement	2015	34
A discrete-choice experiment to elicit preferences of patients with epilepsy for self-management programs Edward Atkinson-Clark, M. Charokopou, Nancy Van Osselaer, Epilepsy & Behavior	2017	20
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective Ling‐Hsiang Chuang, B.G. Verheggen, M. Charokopou, Journal of Medical Economics	2016	18
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan Hiroshi Hagino, Katsuhiro Tanaka, Stuart L. Silverman, Osteoporosis International Bone DiseaseRomosozumab Versus TeriparatideOsteopathySevere Postmenopausal OsteoporosisOrthopaedics	2021	17
A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis Emma Söreskog, F. Borgström, Ingrid Lindberg, Osteoporosis International	2021	15
Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system Mary Geitona, Eugena Stamuli, Stylianos Giannakodimos, Journal of Medical Economics	2019	10
Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland Saku Väätäinen, Erkki Soini, Jukka Peltola, Advances in Therapy	2019	10

Page 1